Clinical Trial Update: Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of NNC0141-0000-0100 in subjects with rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• NNC0141-0000-0100

Snippet

Sponsor: Innate Pharma | Conditions: Inflammation, Rheumatoid Arthritis | Phase 1 | Status: COMPLETED